Study of the VIsual Pathways MODEL for a Better Understanding of Neurodegeneration in Inflammatory and Demyelinating Disorders of Central Nervous System

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

In neuroinflammatory diseases of the central nervous system (CNS) such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and anti-MOG antibody-associated disorders (MOGAD), neuronal degeneration is the consequence of inflammatory and demyelinating lesions in the brain, optic nerve and spinal cord. Both white and grey matter are systematically affected. Lesions of the perivascular spaces containing cerebrospinal fluid (CSF) and meningeal inflammation seem to play an important role in the pathophysiology of these neuroinflammatory diseases. Currently, the interrelation of all these aspects is not clearly established in the pathophysiology of these diseases. In order to better understand the mechanisms that lead to and underlie the clinical disability of patients with these diseases, we need in vivo study models that allow the in-depth study of the neurodegenerative process and the identification of its causes. In this perspective, we make the hypothesis that the visual pathways model is very relevant to measure neuro-axonal loss and to explore the different mechanisms involved in neurodegeneration during MS and other CNS demyelinating diseases. Researchers have at their disposal many tools that allow them to analyse and quantify the neurodegenerative process in a reproducible and very precise manner from a structural and functional point of view, while taking into account possible vascular involvement (MRI, optical coherence tomography - angiography, etc…).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• \- Male or female

• Aged between 18 and 65 years

• Presenting a clinical picture of optic neuritis for less than 4 weeks, confirmed by neuro-ophthalmological assessment

• Patient having given written consent to participate in the study

• Patient with social insurance

• Patient willing to comply with all study procedures and duration

Locations
Other Locations
France
Hop Fontan Chu
RECRUITING
Lille
Contact Information
Primary
Olivier OUTTERYCK, MD
olivier.outteryck@chu-lille.fr
0320445962
Time Frame
Start Date: 2022-10-07
Estimated Completion Date: 2028-04-07
Participants
Target number of participants: 100
Treatments
optic neuritis patients
Patients suffering from an acute episode of optic neuritis will be included. There will be only one group of patients prospectively followed-up.
Sponsors
Leads: University Hospital, Lille

This content was sourced from clinicaltrials.gov